Skip to main content
Top

13-06-2017 | Rheumatoid arthritis | Article

Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis

Journal: The Pharmacogenomics Journal

Authors: S Bek, A B Bojesen, J V Nielsen, J Sode, S Bank, U Vogel, V Andersen

Authors: S Bek, A B Bojesen, J V Nielsen, J Sode, S Bank, U Vogel, V Andersen

Publisher: Nature Publishing Group UK

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects ~1% of the Caucasian population. Over the last decades, the availability of biological drugs targeting the proinflammatory cytokine tumour necrosis factor α, anti-TNF drugs, has improved the treatment of patients with RA. However, one-third of the patients do not respond to the treatment. We wanted to evaluate the status of pharmacogenomics of anti-TNF treatment. We performed a PubMed literature search and all studies reporting original data on associations between genetic variants and anti-TNF treatment response in RA patients were included and results evaluated by meta-analysis. In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA (19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFκB and TNF signalling pathways (including CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3). Explorative prediction analyses found that biomarkers for clinical treatment selection are not yet available.

Pharmacogenomics 2017. doi:10.1038/tpj.2017.26

Literature
1.
Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002; 41: 793–800.CrossRef
2.
Feldmann M, Maini SR . Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7–19.CrossRef
3.
Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M . Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983; 2: 1115–1119.CrossRef
4.
Londei M, Lamb JR, Bottazzo GF, Feldmann M . Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 1984; 312: 639–641.CrossRef
5.
Pujol-Borrell R, Todd I, Doshi M, Bottazzo GF, Sutton R, Gray D et al. HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 1987; 326: 304–306.CrossRef
6.
Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22–32.CrossRef
7.
Smolen JS, Weinblatt ME, van der Heijde D . Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. Ann Rheum Dis 2015; 74: 1567–1570.CrossRef
8.
Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P . New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861–1874.CrossRef
9.
Tarnowski M, Paradowska-Gorycka A, Dabrowska-Zamojcin E, Czerewaty M, Sluczanowska-Glabowska S, Pawlik A . The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy. Expert Opin Drug Metab Toxicol 2016; 12: 41–55.CrossRef
10.
Plant D, Wilson AG, Barton A . Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol 2014; 10: 329–337.CrossRef
11.
Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J et al. Polymorphisms in the toll-like receptor and the IL-23/IL-17 pathways were associated with susceptibility to inflammatory bowel disease in a Danish cohort. PLoS ONE 2015; 10: e0145302.CrossRef
12.
Bek S, Nielsen JV, Bojesen AB, Franke A, Bank S, Vogel U et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Alimen Pharmacol Therap 2016; 44: 554–567.CrossRef
13.
Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J et al. Associations between functional polymorphisms in the NFkappaB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J 2014; 14: 526–534.CrossRef
14.
Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Locht H et al. Genetic variation in the TLR5 locus is associated with anti-TNF response among rheumatoid arthritis patients. Arthritis Rheumatol 2014; 66: S1092–S1093.
15.
Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Locht H et al. Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis. Pharmacogenomics J 2016; doi:10.1038/tpj.2016.66 [Epub ahead of print].
16.
Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Locht H et al. Genetic variations in pattern recognition receptor loci are associated with anti-TNF response in patients with rheumatoid arthritis. PLoS ONE 2015; 10: e0139781.CrossRef
17.
Weng L, Zhang L, Peng Y, Huang RS . Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics 2013; 14: 315–324.CrossRef
18.
Moher D, Liberati A, Tetzlaff J, Altman DG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.CrossRef
19.
Fransen J, van Riel PL . The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23: S93–S99.PubMed
20.
Higgins JP, Thompson SG . Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.CrossRef
21.
Iwaszko M, Swierkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K . Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy. Clin Exp Immunol 2015; 182: 270–277.CrossRef
22.
Canet LM, Filipescu I, Caliz R, Lupianez CB, Canhao H, Escudero A et al. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. Pharmacogenet Genomics 2015; 25: 323–333.CrossRef
23.
Smith SL, Plant D, Lee XH, Massey J, Hyrich K, Morgan AW et al. Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics 2016; 17: 715–720.CrossRef
24.
Iwaszko M, Swierkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K . Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. Joint Bone Spine Revue du Rhumatisme 2016; 83: 75–79.CrossRef
25.
Marquez A, Ferreiro-Iglesias A, Davila-Fajardo CL, Montes A, Pascual-Salcedo D, Perez-Pampin E et al. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. Arthritis Res Therapy 2014; 16: R66.CrossRef
26.
Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW et al. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics 2009; 19: 319–323.CrossRef
27.
Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008; 67: 478–484.CrossRef
28.
Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Canete JD, Raya E, Magro-Checa C et al. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J 2015; 16: 137–140.CrossRef
29.
Canet LM, Caliz R, Lupianez CB, Canhao H, Martinez M, Escudero A et al. Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: a two-stage case–control study. Pharmacogenet Genomics 2015; 25: 432–443.CrossRef
30.
Ceccarelli F, D'Alfonso S, Perricone C, Carlomagno Y, Alessandri C, Croia C et al. The role of eight polymorphisms in three candidate genes in determining the susceptibility, phenotype, and response to anti-TNF therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 2012; 30: 939–942.PubMed
31.
Davila-Fajardo CL, Marquez A, Pascual-Salcedo D, Moreno Ramos MJ, Garcia-Portales R, Magro C et al. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genomics 2014; 24: 1–5.CrossRef
32.
Davila-Fajardo CL, van der Straaten T, Baak-Pablo R, Medarde Caballero C, Cabeza Barrera J, Huizinga TW et al. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics 2015; 16: 373–381.CrossRef
33.
Montes A, Perez-Pampin E, Joven B, Carreira P, Fernandez-Nebro A, Del Carmen Ordonez M et al. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics 2015; 16: 333–345.CrossRef
34.
Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, Takeuchi T et al. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol 2014; 32: 211–217.PubMed
35.
Pinto JA, Rego I, Rodriguez-Gomez M, Canete JD, Fernandez-Lopez C, Freire M et al. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 177–178.PubMed
36.
Potter C, Gibbons LJ, Bowes JD, Cordell HJ, Hyrich K, Isaacs JD et al. Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenet Genomics 2010; 20: 338–341.CrossRef
37.
Cimaz R, Cazalis MA, Reynaud C, Gerloni V, Zulian F, Biggioggero M et al. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann Rheum Dis 2007; 66: 900–904.CrossRef
38.
Coenen MJ, Enevold C, Barrera P, Schijvenaars MM, Toonen EJ, Scheffer H et al. Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. PLoS ONE 2010; 5: e14326.CrossRef
39.
Coulthard LR, Taylor JC, Eyre S, Biologics in Rheumatoid Arthritis Genetics and Genomics Robinson JI, Wilson AG . Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Diseases 2011; 70: 98–103.CrossRef
40.
Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2010; 62: 1849–1861.PubMedPubMedCentral
41.
Hassan B, Maxwell JR, Hyrich KL, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Barton A, Worthington J . Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology 2010; 49: 43–47.CrossRef
42.
Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Soderkvist P et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 448–452.CrossRef
43.
Marotte H, Pallot-Prades B, Grange L, Tebib J, Gaudin P, Alexandre C et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006; 65: 342–347.CrossRef
44.
Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Biologics in Rheumatoid Arthritis G et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 2014; 73: 1202–1210.CrossRef
45.
Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri FF et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatol Int 2008; 28: 901–908.CrossRef
46.
Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 526–529.CrossRef
47.
Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 2012; 64: 665–670.CrossRef
48.
Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 2010; 69: 1315–1320.CrossRef
49.
Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheumatic Dis 2009; 68: 69–74.CrossRef
50.
Schmeling H, Horneff G . Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int 2007; 27: 383–386.CrossRef
51.
Suarez-Gestal M, Perez-Pampin E, Calaza M, Gomez-Reino JJ, Gonzalez A . Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res Therapy 2010; 12: R72.CrossRef
52.
Swierkot J, Bogunia-Kubik K, Nowak B, Bialowas K, Korman L, Gebura K et al. Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Joint Bone Spine Revue du Rhumatisme 2015; 82: 94–99.CrossRef
53.
Tan RJ, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, Wilson AG et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 2010; 69: 1029–1035.CrossRef
54.
Toonen EJ, Coenen MJ, Kievit W, Fransen J, Eijsbouts AM, Scheffer H et al. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1174–1177.CrossRef
55.
Zervou MI, Myrthianou E, Flouri I, Plant D, Chlouverakis G, Castro-Giner F et al. Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population. PLoS ONE 2013; 8: e74375.CrossRef
56.
Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V et al. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 2014; 24: 238–245.PubMed
57.
Maxwell JR, Potter C, Hyrich KL, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Barton A et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008; 17: 3532–3538.CrossRef
58.
Canhao H, Rodrigues AM, Santos MJ, Carmona-Fernandes D, Bettencourt BF, Cui J et al. TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy. BioMed Res Int 2015; 2015: 490295.CrossRef
59.
Acosta-Colman I, Palau N, Tornero J, Fernandez-Nebro A, Blanco F, Gonzalez-Alvaro I et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 2013; 14: 727–734.CrossRef
60.
Honne K, Hallgrimsdottir I, Wu C, Sebro R, Jewell NP, Sakurai T et al. A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis. Arthritis Res Therapy 2016; 18: 12.CrossRef
61.
Julia A, Fernandez-Nebro A, Blanco F, Ortiz A, Canete JD, Maymo J et al. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. Pharmacogenomics J 2015; 16: 147–150.CrossRef
62.
Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 2012; 22: 577–589.CrossRef
63.
Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011; 63: 645–653.CrossRef
64.
Umicevic Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1375–1381.CrossRef
65.
Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C et al. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest 2000; 105: 369–376.CrossRef
66.
Kempinska-Podhorodecka A, Shums Z, Wasilewicz M, Wunsch E, Milkiewicz M, Bogdanos DP et al. TRAF1 gene polymorphism correlates with the titre of Gp210 antibody in patients with primary biliary cirrhosis. Clin Dev Immunol 2012; 2012: 487521.CrossRef
67.
Panoulas VF, Smith JP, Nightingale P, Kitas GD . Association of the TRAF1/C5 locus with increased mortality, particularly from malignancy or sepsis, in patients with rheumatoid arthritis. Arthritis Rheum 2009; 60: 39–46.CrossRef
68.
Hitomi Y, Ebisawa M, Tomikawa M, Imai T, Komata T, Hirota T et al. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J Allergy Clin Immunol 2009; 124: 779–785e776.CrossRef
69.
Lopez-Escamez JA, Saenz-Lopez P, Gazquez I, Moreno A, Gonzalez-Oller C, Soto-Varela A et al. Polymorphisms of CD16A and CD32 Fcgamma receptors and circulating immune complexes in Meniere's disease: a case-control study. BMC Med Genet 2011; 12: 2.CrossRef
70.
Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 2015; 21: 895–905.CrossRef
71.
van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003; 48: 2132–2145.CrossRef
72.
Dennis G Jr., Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res therapy 2014; 16: R90.CrossRef